Back to top

Analyst Blog

Alkermes’ (ALKS - Analyst Report) product portfolio as well as pipeline has been strengthened following its purchase of  Elan Corporation’s Elan Drug Technologies unit. The company primarily focuses on developing therapies to treat disorders such as addiction, schizophrenia and depression, which affect the central nervous system.

The key marketed products at Alkermes include Risperdal Consta (schizophrenia and bipolar disorder), Xeplion (schizophrenia), Vivitrol (opioid and alcohol dependence), Ampyra/Fampyra (improving walking ability in multiple sclerosis patients) and Bydureon (type II diabetes).

Alkermes appointed Dr. Serge Stankovic as a senior Vice President of clinical development and medical affairs to manage the development of its expanded pipeline more efficiently. The management team at Alkermes now has another new addition in the form of Peter Norman. Norman has been recruited as the Vice President of government affairs and policy. Both Norman and Stankovic, with their vast experience, are expected to help Alkermes reach greater heights.

We are pleased with the company’s efforts to develop its pipeline. Interesting candidates include aripiprazole lauroxil for treating schizophrenia, ALKS 5461 (a combination of ALKS 33 and buprenorphine) for major depressive disorder, ALKS 3831 (schizophrenia) and a three-month formulation of Invega sustenna.

Alkermes is also advancing the development of the early-stage candidates in its pipeline. The appointment of Stankovic, who has donned many important roles pertaining to research and development in his illustrious career, is expected to be beneficial to Alkermes’ pipeline development efforts. Stankovic was associated with companies like Teva Pharmaceutical (TEVA - Analyst Report) previously.

Alkermes currently carries a Zacks Rank #2 (Buy). Akorn, Inc. (AKRX - Snapshot Report) is another Zacks #2 Ranked stock.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%